Acute Pain
Volume 9, Issue 1 , Pages 21-34 , March 2007

Opioid-induced hyperalgesia—Pathophysiology and clinical relevance

Received 6 April 2006 ,Revised 27 October 2006 ,Accepted 9 November 2006.

References 

  1. Beck PW, Handwerker HO. Bradykinin and serotonin effects on various types of cutaneous nerve fibers. Pflug Arch. 1974;347:209–222
  2. Bessou P, Perl ER. Responses of cutaneous sensory units with unmyelinated fibers to noxious stimuli. J Neurophysiol. 1969;32:1025–1043
  3. Meyer RA, Campbell JN. Myelinated nociceptive afferents account for the hyperalgesia that follows a burn to the hand. Science. 1981;213:1527–1529
  4. Reeh PW, Bayer J, Kocher L, Handwerker HO. Sensitization of nociceptive cutaneous nerve fibers from the rat's tail by noxious mechanical stimulation. Exp Brain Res. 1987;65:505–512
  5. Schmelz M, Schmidt R, Ringkamp M, Forster C, Handwerker HO, Torebjörk HE. Limitation of sensitization to injured parts of receptive fields in human skin C-nociceptors. Exp Brain Res. 1996;109:141–147
  6. Schmidt R, Schmelz M, Forster C, Ringkamp M, Torebjörk HE, Handwerker HO. Novel classes of responsive and unresponsive C nociceptors in human skin. J Neurosci. 1995;15:333–341
  7. Ali Z, Meyer RA, Campbell JN. Secondary hyperalgesia to mechanical but not heat stimuli following a capsaicin injection in hairy skin. Pain. 1996;68:401–411
  8. LaMotte RH, Shain CN, Simone DA, Tsai EFP. Neurogenic hyperalgesia psychophysical studies of underlying mechanisms. J Neurophysiol. 1991;66:190–211
  9. Raja SN, Campbell JN, Meyer RA. Evidence for different mechanisms of primary and secondary hyperalgesia following heat injury to the glabrous skin. Brain. 1984;107:1179–1188
  10. Simone DA, Baumann TK, LaMotte RH. Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain. 1989;38:99–107
  11. Dickenson AH. Spinal cord pharmacology of pain. Brit J Anaesth. 1995;75:193–200
  12. Schaible HG, Grubb B, Neugebauer V, Oppmann M. The effects of NMDA antagonists on neuronal activity in cats spinal cord evoked by acute inflammation in the knee joint. Eur J Neurosci. 1991;3:981–991
  13. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-d-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. Pain. 1991;44:293–299
  14. Abram SE, Yaksh T. Morphine, but not inhalation anesthesia, blocks post-injury facilitation. Anesthesiology. 1993;78:713–721
  15. Dahl JB, Kehlet H. The value of pre-emptive analgesia in the treatment of postoperative pain. Brit J Anaesth. 1993;70:434
  16. Dahl JB, Rosenberg J, Dirkes WE, Morgensen T, Kehlet H. Prevention of postoperative pain by balanced analgesia. Brit J Anaesth. 1990;64:518–520
  17. Kehlet H. Surgical stress: the role of pain and analgesia. Brit J Anaesth. 1989;63:189–195
  18. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Brit J Anaesth. 1997;708:606–617
  19. Kehlet H, Dahl JB. The value of multimodal or balanced analgesia in postoperative pain treatment. Anesth Analg. 1993;77:1048–1056
  20. Woolf CJ, Chong MS. Preemptive analgesia—treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg. 1993;77:362–379
  21. Kest B, Sarton E, Dahan A. Gender-differences in opioid-mediated analgesia: animal and human studies. Anesthesiology. 2000;93:539–547
  22. Pleym H, Spigset O, Kharasch ED, Dale O. Gender differences in drug effects: implications for anesthesiologists. Acta Anaesthesiol Scand. 2003;47:241–259
  23. Freye E, Latasch L. Toleranzentwicklung unter opioidgabe—molekulare mechanismen und klinische bedeutung. Anästhesiol Intensivmed Notfallmed Schmerzther. 2003;38:14–26
  24. Kissin I, Bright CA, Bradley EL. Can inflammatory pain prevent the development of acute tolerance to alfentanil?. Anesth Analg. 2001;92:1296–1300
  25. Ali NM. Hyperalgesic response is a patient receiving high concentrations of spinal morphine. Anesthesiology. 1986;65:449–450
  26. Arner S, Rawal N, Gustafsson LL. Clinical experience of long-term treatment with epidural and intrathecal opioids—a nationwide survey. Acta Anaesthesiol Scand. 1988;32:253–259
  27. Doverty M, White JM, Somogyi AA, Bochner F, Ali R, Ling W. Hyperalgesic responses in methadone maintenance patients. Pain. 2001;90:91–96
  28. Guignard B, Bossard AE, Coste C, Sessler DI, Lebrault C, Alfonsi P, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93:409–417
  29. Angst MS, Clark JD. Opioid-induced hyperalgesia. Anesthesiology. 2006;104:570–587
  30. Celerier E, Laulin J, Larcher A, Le Moal M, Simonnet G. Evidence for opiate-activated NMDA processes masking opiate analgesia in rats. Brain Res. 1999;847:18–25
  31. Colpaert FC. System theory of pain and of opiate analgesia: no tolerance to opiates. Pharmacol Rev. 1996;48:402
  32. Ossipov MH, Lai J, Vanderah TW, Porreca F. Induction of pain facilitation by sustained opioid exposure: relationship to opioid antinociceptive tolerance. Life Sci. 2003;73:783–800
  33. Simonnet G, Rivat C. Opioid-induced hyperalgesia: abnormal or normal pain. Neuroreport. 2003;14:1–7
  34. Solomon RL, Corbit JD. An opponent-process theory of motivation. Psychol Rev. 1974;81:119–145
  35. Connor M, Christie MJ. Opiod receptor signalling mechanisms. Clin Exp Pharmacol Physiol. 1999;26:493–499
  36. Claphan DE, Neer DJ. G protein βγ subunits. Annu Rev Pharmacol Toxicol. 1997;37:167–203
  37. Aimone LD, Yaksh TL. Opioid modulation of capsaicin-evoked release of substance P from rat spinal cord in vivo. Peptides. 1989;10:1127–1131
  38. Chang HM, Berde CB, Holz GG, Steward GF, Kream RM. Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology. 1989;70:672–677
  39. Trafton JA, Abbadie C, Marchand S, Mantyh PW, Basbaum AI. Spinal opioid analgesia: how critical is the regulation of substance P signaling. J Neurosci. 1999;19:9642–9653
  40. Borgland SL. Acute opioid receptor desensitization and tolerance: is there a link?. Clin Exp Pharmacol Physiol. 2001;28:147–154
  41. He L, Fong J, von Zastrow M. Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell. 2002;108:271–282
  42. Kieffer BL, Evans CJ. Opioid tolerance—in search of the holy grail. Cell. 2002;108:587–590
  43. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kag L, et al. Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem. 1996;271:19021–19024
  44. Whistler J, Chuang HH, Chu P, Jan LY, von Zastrow M. Functional dissociation of m opioid receptor signalling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron. 1999;23:737–746
  45. Fields HL, Bry J, Hentall I, Zorman G. The activity of neurons in the rostral medulla of the rat during withdrawal from noxious heat. J Neurosci. 1983;3:2545–2552
  46. Fields HL, Heinricher MM. Anatomy and physiology of a nociceptive modulatory system. Philos Trans R Soc Lond B: Biol Sci. 1985;308:361–374
  47. Morgan MM, Fields HL. Pronounced changes in the activity of nociceptive modulatory neurons in the rostral ventromedial medulla in response to prolonged thermal noxious stimuli. J Neurophysiol. 1994;72:1161–1170
  48. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci. 1991;14:219–245
  49. Heinricher MM, Morgan MM, Fields HL. Direct and indirect actions of morphine on medullary neurons that modulate nociception. Neuroscience. 1992;48:533–543
  50. Heinricher MM, Morgan MM, Tortorici V, Fields HL. Disinhibition of Off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla. Neuroscience. 1994;63:279–288
  51. Chieng B, Williams JT. Increased opioid inhibition of GABA release in nucleus accumbens during morphine withdrawal. J Neurosci. 1998;18:7033–7039
  52. Dickenson AH, Chapman V, Green GM. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen Pharmacol. 1997;28:633–638
  53. Duttaroy A, Yoburn BC. The effects of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995;82:1226–1236
  54. Basbaum AI. Distinct neurochemical features of acute and persistent pain. Proc Natl Acad Sci USA. 1999;96:7739–7743
  55. Martin WJ, Liu H, Wang H, Malmberg AB, Basbaum AI. Inflammation-induced up-regulation of protein kinase Cgamma immunoreactivity in rat spinal cord correlates with enhanced nociceptive processing. Neuroscience. 1999;88:1267–1274
  56. Mayer DJ, Mao J, Holt J, Price DD. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA. 1999;96:7731–7736
  57. Mayer DJ, Mao J, Price DD. The development of morphine tolerance and dependence is associated with translocation of protein kinase C. Pain. 1995;61:365–374
  58. Appleyard SM, Celver JP, Pineda V, Kovoor A, Wayman GA, Chavkin C. Agonist-dependent desensitization of the kappa opioid receptor by G protein receptor kinase and beta-arrestin. J Biol Chem. 2003;27:23802–23807
  59. Kovoor A, Celver JP, Wu A, Chavkin C. Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol. 1998;54:704–711
  60. Bot G, Blake AD, Li S, Reisine T. Fentanyl and its analogs desensitize the cloned mu opioid receptor. J Pharmacol Exp Ther. 1998;285:1207–1218
  61. Keith DE, Anton B, Murray SR, Zaki PA, Chu PC, Lissin DV, et al. mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechansim in vitro and in the mammalian brain. Mol Pharmacol. 1998;53:377–384
  62. Angers S, Salahpour A, Bouvier M. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol. 2002;42:409–435
  63. Jordan BA, Devi LA. G-protein coupled receptor heterodimerization modulates receptor function. Nature. 1999;399:700
  64. Avidor-Reiss T, Nevo I, Levy R, Pfuffer T, Vogel Z. Chronic opioid treatment induces adenyl cyclase V superactivation. J Biol Chem. 1996;271:21309–21315
  65. Crain SM, Shen KF. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci. 1998;19:358–365
  66. Sharma SJ, Klee WA, Nirenberg M. Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci USA. 1975;72:590–594
  67. Fairbanks CA, Wilcox GL. Spinal plasticity of acute opioid tolerance. J Biomed Sci. 2000;7:200–212
  68. Li X, Clark JD. Hyperalgesia during opioid abstinence: mediation by glutamate and substance P. Anesth Analg. 2002;95:979–984
  69. Ingram SL, Vaughan CW, Bagley EE, Connor M, Christie MJ. Enhanced opioid efficacy in opioid dependence is due to an additional signal transduction pathway. J Neurosci. 1998;18:10269–10276
  70. Vaughan CW, Ingram SL, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature. 1997;360:611–614
  71. Kissin I, Brown PT, Bradley EL. Does midazolam inhibit the development of acute tolerance to the analgesic effect of alfentanil?. Life Sci. 1992;52:55–60
  72. Kissin I, Lee SS, Arthur GR, Bradley EL. Effect of midazolam on development on acute tolerance to alfentanil: the role of pharmacokinetic interactions. Anesth Analg. 1997;85:182–187
  73. Luger TJ, Hayashi T, Lorenz IH, Hill HF. Mechanisms of the influence of midazolame on morphine antinociception at spinal and supraspinal levels in rats. Eur J Pharmacol. 1994;271:421–431
  74. Luger TJ, Hayashi T, Weiss CG, Hill HF. The spinal potentiating effect and the supraspinal inhibitory effect of midazolam on opioid-induced analgesia. Eur J Pharmacol. 1995;275:153–162
  75. Tejwani GA, Rattan AK, Sribanditmongkol P, Sheu MJ, Zuniga J, McDonald JS. Inhibition of morphine-induced tolerance and dependence by a benzodiazepine receptor agonist midazolam in the rat. Anesth Analg. 1993;76:1052–1060
  76. Hahnenkamp K, Nollet J, van Aken H, Buerkle H, Halene T, Schauerte S, et al. Remifentanil directly activates human N-methyl-d-aspartate receptors expressed in xenopus laevis oocytes. Anesthesiology. 2004;100:1531–1537
  77. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-l-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994;56:69–75
  78. Kolesnikov YA, Pick CG, Ciszewska G, Pasternak GW. Blockade of tolerance to morphine but not to k opioids by a nitric oxide synthese inhibitor. Proc Natl Acad Sci USA. 1993;90:5162–5166
  79. Majeed NH, Przewlocka B, Machelska H, Przewlocki R. Inhibition of nitric oxide synthetase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacology. 1994;32:189–192
  80. Przewlocki R, Machelska H, Przewlocka B. Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. Life Sci. 1993;53:1–5
  81. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1–13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA. 1979;76:6666–6670
  82. Faden AI. Dynorphin increases extracellular levels of excitatory amino acids in the brain trough a non-opioid mechanism. J Neurosci. 1992;12:425–429
  83. Gardell LR, Wang R, Burgess SE, Ossipov MH, Vanderah TW, Malan TP, et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J Neurosci. 2002;22:6747–6755
  84. Skilling SR, Sun X, Kurtz HJ, Larson AA. Selective potentiation on NMDA-induced activity and release of excitatory amino acids by dynorphin: possible roles in paralysis and neurotoxicity. Brain Res. 1992;575:272–278
  85. Benoliel JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M, Cesselin F. Differential inhibitory/stimulatory modulation of spinal CCK release by mu and delta opioid agonists, and selective blockade of mu-dependent inhibition by kappa receptor stimulation. Neurosci Lett. 1991;124:204–207
  86. Bourgoin S, Benoliel JJ, Collin E, Mauborgne A, Pohl M, Hamon M, et al. Opioidergic control of the spinal release of neuropetides. Possible significance for the analgesic effects of opioids. Fundam Clin Pharmacol. 1994;8:307–321
  87. Devillers JP, Labrouche SA, Castes E, Simonnet G. Release of neuropeptide FF, an anti-opioid peptide, in rat spinal cord slices is voltage- and Ca(2+)-sensitive: possible involvement of P-type Ca2+ channels. J Neurochem. 1995;64:1567–1575
  88. Devillers JP, Boisserie F, Laulin JP, Larcher A, Simonnet G. Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Brain Res. 1995;700:173–181
  89. Gouarderes C, Tafani JA, Meunier JC, Jhamandas K, Zajac JM. Nociceptin receptors in the rat spinal cord during morphine tolerance. Brain Res. 1999;838:85–94
  90. Rattan AK, Tejwani GA. Effect of chronic treatment with morphine, midazolame and both together on dynorphin(1–3) levels in the rat. Brain Res. 1997;754:239–244
  91. Xu XJ, Puke MJC, Verge VMK, Wiesenfeld-Hallin Z, Hughes J, Hokfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci Lett. 1993;152:129–132
  92. Yang HY, Fratta W, Majane EA, Costa E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci USA. 1985;82:7757–7761
  93. Yuan L, Han Z, Chang JK, Han JS. Accelerated release and production of orphanin FQ in the brain of chronic morphine tolerant rats. Brain Res. 1999;826:330–334
  94. Rizzi A, Bigoni R, Marzola G, Guerrini R, Salvadori S, Regoli D, et al. The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1–13)NH2, potentiates morphine analgesia. Neuroreport. 2000;11:2369–2372
  95. Vanderah TW, Gardell LR, Burgess SE, Ibrahim M, Dogrul A, Zhong CM, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci. 2000;20:7074–7079
  96. Vanderah TW, Ossipov MH, Lai J, Malan TP, Porreca F. Mechanisms of opioid-induced pain and antinociceptive tolerance: descending facilitation and spinal dynorphin. Pain. 2001;92:5–9
  97. Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science. 1984;224:395–396
  98. Watkins LR, Kinscheck IB, Mayer DJ. Potentiation of morphine analgesia by the cholecystokinin antagonists proglumide. Brain Res. 1985;327:169–180
  99. Kaplan H, Fields HL. Hyperalgesia during acute opioid abstinence: evidence for a nociceptive facilitating function of the rostral ventromedial medulla. J Neurosci. 1991;11:1433–1439
  100. Vanderah TW, Suenaga NMH, Ossipov MH, Malan TP, Lai J, Porreca F. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J Neurosci. 2001;21:279–286
  101. Heinricher MM, McGaraughty S, Grandy DK. Circuitry underlying antiopioid action of orphanin FQ in the rostral ventromedial medulla. J Neurophysiol. 1997;78:3351–3358
  102. Heinricher MM, McGaraughty S, Tortorici V. Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol. 2001;85:280–286
  103. Bie B, Pan ZZ. Presynaptic mechanism for anti-analgesic and anti-hyperalgesic actions of k-opioid receptors. J Neurosci. 2003;23:7262–7268
  104. Dourish CT, O’Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol. 1990;176:35–44
  105. Zarrindast MR, Nikfar S, Rezayat M. Cholecystokinin receptor mechanism(s) and morphine tolerance in mice. Pharmacol Toxicol. 1999;84:46–50
  106. Price DD, von der Gruen A, Miller J, Rafii A, Price D. Potentiation of systemic morphine analgesia in humans by proglumide, a cholecystokinin antagonist. Anesth Analg. 1985;64:801–806
  107. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987;41:2845–2849
  108. Shimomura K, Kamata O, Ueki S, Ida S, Oguri K. Analgesic effects of morphine glucuronides. Tohoku J Exp Med. 1971;105:45–52
  109. Smith MT, Watt JA, Crammond T. Morphine-3-glucuronide—a potent antagonist of morphine analgesia. Life Sci. 1990;47:579–585
  110. Yaksh TL, Harty GJ. Pharmakology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther. 1998;244:501–507
  111. Celerier E, Rivat C, Jun Y, Laulin JP, Larcher A, Reynier P, et al. Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology. 2000;92:465–472
  112. Rivat C, Laulin JP, Corcuff JB, Celerier E, Pain L, Simonnet G. Fentanyl enhancement of carrageenan-induced long-lasting hyperalgesia in rats: prevention by the N-methyl-d-aspartate receptor antagonist ketamine. Anesthesiology. 2002;96:381–391
  113. Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002;94:1263–1269[table]
  114. Richebe P, Rivat C, Laulin JP, Maurette P, Simonnet G. Acute morphine tolerance in rats operated under fentanyl. Preventive effect of ketamine. Anesthesiology. 2003;99:A941
  115. Richebe P, Rivat C, Creton C, Maurette P, Simonnet G. Nitrous oxide revisited: preventive effects on fentanyl induced hyperalgesia and morphine acute tolerance. Anesthesiology. 2003;99:A940
  116. Chia YY, Liu K, Wang JJ, Kuo MC, Ho ST. Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can J Anaesth. 1999;46:872–877
  117. Kissin I, Bright CA, Bradley EL. Acute tolerance to continuously infused alfentanil: the role of cholecystokinin and N-methyl-d-aspartate-nitric oxide systems. Anesth Analg. 2000;91:110–116
  118. Kissin I, Lee SS, Arthur GR, Bradley EL. Time course characteristics of acute tolerance development to continuously infused alfentanil in rats. Anesth Analg. 1996;83:600–605
  119. Kissin I, Bright CA, Bradley EL. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations?. Anesth Analg. 2000;91:1483–1488
  120. Schraag S, Checketts MR, Kenny GN. Lack of rapid development of opioid tolerance during alfentanil and remifentanil infusions for postoperative pain. Anesth Analg. 1999;89:753–757
  121. Vinik HR, Kissin I. Rapid development of tolerance to analgesia during remifentanil infusion in human. Anesth Analg. 1998;86:1307–1311
  122. Gustorff B, Felleiter P, Nahlik G, Brannath W, Hoerauf KH, Spacek A, et al. The effect of remifentanil on the heat pain threshold in volunteers. Anesth Analg. 2001;92:369–374
  123. Gustorff B, Nahlik G, Hoerauf KH, Kress HG. The absence of acute tolerance during remifentanil infusion in volunteers. Anesth Analg. 2002;94:1223–1228
  124. Soltesz S, Biedler A, Silomon M, Schöpflin I, Molter GP. Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. Brit J Anaesth. 2001;86:763–768
  125. Wilhelm W, Dorscheid E, Schlaich N, Niederprüm P, Deller D. Remifentanil zur analgosedierung von intensivpatienten. Anaesthesist. 1999;48:625–629
  126. Cortinez LI, Brandes V, Munoz HR, Guerrero ME, Mur M. No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia. Brit J Anaesth. 2001;87:866–869
  127. Angst MS, Koppert W, Pahl I, Clark JD, Schmelz M. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain. 2003;106:49–57
  128. Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg. 2003;97:810–815
  129. Koppert W, Angst MS, Alsheimer M, Sittl R, Albrecht S, Schüttler J, et al. Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain. 2003;106:91–99
  130. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schüttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology. 2003;99:152–159
  131. Guignard B, Coste C, Costes H, Sessler DI, Lebrault C, Morris W, et al. Supplementing desflurane-remifentanil anesthesia with small-dose ketamine reduces perioperative opioid analgesic requirements. Anesth Analg. 2002;95:103–108[table]
  132. Luginbühl M, Gerber A, Schnider TW, Petersen-Felix S, Arendt-Nielsen L. Modulation of remifentanil-induced analgesia, hyperalgesia and tolerance by small-dose ketamine in humans. Anesth Analg. 2003;96:726–732
  133. Mao J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci. 1994;14:2301–2312
  134. Stillman MJ, Moulin DE, Foley KM. Paradoxical pain following high-dose spinal morphine. Pain. 1987;4:
  135. Li X, Angst MS, Clark JD. Opioid-induced hyperalgesia and incisional pain. Anesth Analg. 2001;93:204–209
  136. Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res. 2001;86:56–62
  137. Manning B, Mao J, Frenk H, Price DD, Mayer DJ. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 1996;67:79–88
  138. Mao J, Price DD, Caruso F, Mayer DJ. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain. 1996;67:361–368
  139. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 1995;62:259–274
  140. Adriaenssens G, Vermeyen KM, Hoffmann VL, Mertens E, Adriaensen HF. Postoperative analgesia with i.v. patient-controlled morphine: effect of adding ketamine. Brit J Anaesth. 1999;83:393–396
  141. Katz NP. Morphidex (MS:DM) double-blind, multiple-dose studies in chronic pain patients. J Pain Symptom Manage. 2000;19:S37–S41
  142. Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg. 2003;96:789–795
  143. Sjogren P, Dragsted L, Christensen CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand. 1993;37:780–782
  144. Smith GD, Smith MT. Morphin-3-glucuronide: evidence to support its role in the development of tolerance to the antinozizeptive effects of morphine in the rat. Pain. 1995;62:51–60
  145. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27:524–528
  146. Sjogren P, Jensen NH, Jensen TS. Disappearence of morphine-induced hyperalgesia after discontinuing or substituting with other opioid agonists. Pain. 1994;59:313–316
  147. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995;187:165–168
  148. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett. 1997;223:1–4
  149. Carpenter KJ, Chapman V, Dickenson AH. Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo. Eur J Pain. 2000;4:19–26
  150. Bulka A, Plesan A, Xu XJ, Wiesenfeld-Hallin Z. Reduced tolerance to the anti-hyperalgesic effect of methadone in comparison to morphine in a rat model of mononeuropathy. Pain. 2002;95:103–109
  151. Doverty M, Somogyi AA, White JM, Bochner F, Beare CH, Menelaou A, et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. Pain. 2001;93:155–163
  152. Davis AM, Inturrisi CE. d-methadone blocks morphine tolerance and N-methyl-d-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999;289:1048–1053
  153. Stevens CW, Yaksh TL. Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. J Pharmacol Exp Ther. 1989;250:1–8
  154. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001;63:139–146
  155. Clark JD. Comment on: Doverty et al., hyperalgesic responses in methadone maintenance patients. Pain. 2002;99:608–609
  156. Larcher A, Laulin JP, Celerier E, Le Moal M, Simonnet G. Acute tolerance associated with a single opiate administration: involvement of N-methyl-d-aspartate-dependent pain facilitatory systems. Neuroscience. 1998;84:583–589
  157. Laulin JP, Larcher A, Celerier E, Le Moal M, Simonnet G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci. 1998;10:782–785
  158. Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci. 2001;21:4074–4080
  159. Laulin JP, Celerier E, Larcher A, Le Moal M, Simonnet G. Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. Neuroscience. 1999;89:631–636
  160. Schmid RL, Sandler AN, Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: a review of current techniques and outcomes. Pain. 1999;82:111–125
  161. Chia YY, Liu K, Chow LH, Lee TY. The preoperative administration of intravenous dextromethorphan reduces postoperative morphine consumption. Anesth Analg. 1999;89:752
  162. Weinbroum AA, Bender B, Bickels J, Nirkin A, Marouani N, Chazam S, et al. Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient-controlled epidural analgesia requirement: a randomized, placebo-controlled, double-blind study in lower-body bone malignancy-operated patients. Cancer. 2003;97:2334–2340
  163. Weinbroum AA, Gorodetzky A, Nirkin A, Kollender Y, Bickels J, Marouani N, et al. Dextromethorphan for the reduction of immediate and late postoperative pain and morphine consumption in orthopedic oncology patients: a randomized, placebo-controlled, double-blind study. Cancer. 2002;95:1164–1170
  164. Bernard JM, Hommeril JL, Passuti N, Pinaud M. Postoperative analgesia by intravenous clonidine. Anesthesiology. 1991;75:577–582
  165. De Kock MF, Crochet B, Morimont C, Scholtes JL. Intravenous or epidural clonidine for intra and postoperative analgesia. Anesthesiology. 1993;79:525–531
  166. De Kock MF, Pichon G, Scholtes JL. Intraoperative clonidine enhances postoperative morphine patient-controlled analgesia. Can J Anaesth. 1992;39:537–544
  167. Spaulding TC, Fielding S, Venafro JJ, Lal H. Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur J Pharmacol. 1979;58:19–25
  168. Fairbanks CA, Wilcox GL. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J Pharmacol Exp Ther. 1999;288:1107–1116
  169. Gowing LR, Farrell M, Ali RL, White JM. alpha2-Adrenergic agonists in opioid withdrawal. Addiction. 2002;97:49–58
  170. Bie B, Fields HL, Williams JT, Pan ZZ. Roles of a1- and a2-adrenoreceptors in the nucleus raphe magnus in opioid analgesia and opioid abstinence-induced hyperalgesia. J Neurosci. 2003;23:7950–7957
  171. Joshi W, Connelly NR, Reuben SS, Wolckenhaar M, Thakkar N. An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth Analg. 2003;97:35–38
  172. Reuben SS, Bhopatkar M, Maciolek H, Joshi W, Sklar J. Preemptive analgesic effect of refecoxib after ambulatory arthroscopic knee surgery. Anesth Analg. 2002;94:55–59
  173. Moore A, Collins S, Collins D, McQuay H, Edwards J. Single dose paracetamol (acetaminophen), with and without codeine, for postoperative pain. Cochrane Syst Rev. 1998;1–9
  174. Hyllested M, Jones S, Pedersen JL, Kehlet H. Comparative effect of paracetamol. NSAIDs or their combination in postoperative pain management: a qualitative review. Brit J Anaesth. 2002;88:199–214
  175. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992;257:1276–1279
  176. Malmberg AB, Yaksh TL. Cyclooxygenase inhibition and the spinal release of prostaglandin E2 and amino acids evoked by paw formalin injection: a microdialysis study in unanesthetized rats. J Neurosci. 1995;15:2768–2776
  177. Tröster A, Sittl R, Singler B, Schmelz M, Schüttler J, Koppert W. Modulation of remifentanil-induced analgesia and post-infusion hyperalgesia by parecoxib in humans. Anesthesiology. 2006;105:1016–1023
  178. Lee SC, Wang JJ, Ho ST, Tao PL. Nalbuphine coadministered with morphine prevents tolerance and dependence. Anesth Analg. 1997;84:810–815
  179. Tao PL, Hwang CL, Chen CY. U-50,488 blocks the development of morphine tolerance and dependence at very low dose in mice. Eur J Pharmacol. 1994;256:281–286
  180. Yamamoto T, Ohno M, Ueki S. A selective k-agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats. Eur J Pharmacol. 1988;156:173–176
  181. Likar R, Griessinger N, Sadjak A, Sittl R. Transdermales buprenorphin für die behandlung chronischer tumor- und nicht-tumorschmerzen. Wien Med Wochenschr. 2003;153:317–322
  182. Koppert W, Ihmsen H, Koerber N, Wehrfritz A, Sittl R, Schmelz M, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005;118:15–22
  183. Bruera E, Peirera J, Watanabe C, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78:852–857
  184. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86:1856–1866
  185. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. Acta Anaesthesiol Scand. 1999;43:918–923
  186. Morley JS, Watt JW, Wells JC, Miles JB, Finnegan MJ, Leng G. Methadone in pain uncontrolled by morphine. Lancet. 1993;342:1243
  187. Williams PI, Sarginson RE, Ratcliffe JM. Use of methadone in the morphine-tolerant burned paediatric patient. Brit J Anaesth. 1998;80:92–95
  188. Kelly DJ, Ahmad M, Brull SJ. Preemptive analgesia. I: Physiological pathways and pharmacolocigal modalities. Can J Anaesth. 2001;48:1000–1010
  189. Kelly DJ, Ahmad M, Brull SJ. Preemptive analgesia. II: Recent advances and current trends. Can J Anaesth. 2001;48:1091–1101
  190. Moiniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief. Anesthesiology. 2002;96:725–741

PII: S1366-0071(06)00204-X

doi: 10.1016/j.acpain.2006.11.001

Acute Pain
Volume 9, Issue 1 , Pages 21-34 , March 2007

Article Tools

* Image Usage & Resolution